Page last updated: 2024-12-05

1,4-bis(2-(3,5-dichloropyridyloxy))benzene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,4-bis(2-(3,5-dichloropyridyloxy))benzene is a chemical compound with the molecular formula C16H8Cl4N2O2. It is also known by its common name, **bis(3,5-dichloropyridyl) ether**.

This compound is important in research due to its **potential applications in various fields**:

**1. Pesticide Development:**

* **Herbicidal activity:** Bis(3,5-dichloropyridyl) ether exhibits herbicidal activity, which means it can kill or inhibit the growth of unwanted plants. This property makes it a potential candidate for development as a new herbicide.
* **Mechanism of action:** The herbicidal action of this compound is related to its ability to interfere with the synthesis of chlorophyll, a crucial molecule for plant photosynthesis.

**2. Pharmaceuticals:**

* **Antimicrobial activity:** Research has indicated that bis(3,5-dichloropyridyl) ether may possess antimicrobial activity against certain bacteria and fungi. This property makes it a potential lead compound for developing new antimicrobial drugs.

**3. Materials Science:**

* **Organic semiconductors:** The unique structural features of this compound, such as its aromatic rings and halogen atoms, make it a promising candidate for use in organic electronics. It could potentially be used in the development of organic semiconductors for applications like organic light-emitting diodes (OLEDs) or solar cells.

**4. Environmental Science:**

* **Degradation and bioaccumulation:** Studying the degradation and bioaccumulation properties of bis(3,5-dichloropyridyl) ether is important for understanding its potential environmental impact. This information is crucial for ensuring the safe use and disposal of the compound.

**Ongoing Research:**

Active research on bis(3,5-dichloropyridyl) ether focuses on:

* Optimizing its herbicidal activity for agricultural applications.
* Exploring its potential as a pharmaceutical agent.
* Investigating its properties for use in organic electronics.
* Assessing its environmental impact and developing strategies for its safe management.

**Overall, 1,4-bis(2-(3,5-dichloropyridyloxy))benzene holds great potential for diverse applications across multiple fields. Further research will determine its specific roles and applications in these areas.**

1,4-bis(2-(3,5-dichloropyridyloxy))benzene: potent phenobarbital-like inducer of microsomal monooxygenase activity; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5382
CHEMBL ID488803
SCHEMBL ID240269
MeSH IDM0091610

Synonyms (86)

Synonym
BIDD:PXR0116
gtpl2756
2,2'-[1,4-phenylenebis(oxy)]bis(3,5-dichloropyridine)
MLS000532100 ,
smr000137041
2,2'-[benzene-1,4-diylbis(oxy)]bis(3,5-dichloropyridine)
76150-91-9
EU-0101174
tcpobop, >=98% (hplc), solid
1,4-bdpob
2,2'-(1,4-phenylenebis(oxy))bis(3,5-dichloropyridine)
ccris 3521
pyridine, 2,2'-(1,4-phenylenebis(oxy))bis(3,5-dichloro-
1,4-bis(2-(3,5-dichloropyridyloxy))benzene
NCGC00016001-01
lopac-t-1443
LOPAC0_001174
3,5-dichloro-2-{4-[(3,5-dichloropyridin-2-yl)oxy]phenoxy}pyridine
TCD ,
SPECTRUM5_002035
tcpobop
NCGC00094431-04
1,4-bis[2-(3,5-dichloropyridyloxy)]benzene
NCGC00094431-03
NCGC00094431-02
NCGC00094431-01
STK018912
NCGC00016001-02
1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene
T 1443
NCGC00016001-06
CHEMBL488803
3,5-dichloro-2-[4-(3,5-dichloropyridin-2-yl)oxyphenoxy]pyridine
AKOS001026934
HMS3263L09
HMS2488C03
NCGC00256438-01
cas-76150-91-9
tox21_302870
dtxsid8020175 ,
dtxcid00175
NCGC00257722-01
tox21_200168
CCG-205248
NCGC00016001-05
NCGC00016001-03
NCGC00016001-04
NCGC00016001-07
F3284-1261
1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene
unii-p4r368gdd7
p4r368gdd7 ,
LP01174
S6895
pyridine,2,2'-[1,4-phenylenebis(oxy)]bis[3,5-dichloro-
SCHEMBL240269
NCGC00261859-01
1,4-bis[(3,5-dichloropyridin-2-yl)oxy]benzene
tox21_501174
1,4-bis(3,5-dichloro-2-pyridinyloxy)benzene
2-[4-[3,5-bis(chloranyl)pyridin-2-yl]oxyphenoxy]-3,5-bis(chloranyl)pyridine
cid_5382
bdbm89873
3,5-dichloro-2-[4-[(3,5-dichloro-2-pyridyl)oxy]phenoxy]pyridine
3,5-dichloro-2-[4-[(3,5-dichloro-2-pyridinyl)oxy]phenoxy]pyridine
mfcd00057368
pyridine, 2,2'-[1,4-phenylenebis(oxy)]bis[3,5-dichloro-
Z56756152
SR-01000076146-5
sr-01000076146
SR-01000076146-1
1,4-bis(3,5-dichloropyridin-2-yloxy)benzene
E75951
FT-0715320
Q27088948
SDCCGSBI-0051141.P002
NCGC00016001-10
CS-0026101
HY-103243
BS-49261
SB52243
BDA15091
EN300-55045
2,2'-[1,4-phenylenebis(oxy)]bis[3,5-dichloropyridine]
1,4-bis(3,5-dichloro-2-pyridyloxy)benzene
3,5-dichloro-2-[4-[(3,5-dichloropyridin-2-yl)oxy]phenoxy]pyridine

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These results suggest an innovative therapeutic approach for treating the adverse effects of acetaminophen and potentially other hepatotoxic agents."( Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR.
Chua, SS; Huang, W; Moore, DD; Wei, P; Zhang, J, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Dose-response induction of mice hepatic microsomal cytochrome P-450, aldrin epoxidase and dimethylaminoantipyrine N-demethylase gave ED50 values for TCPOBOP and five homologs."( 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) and related compounds as inducers of hepatic monooxygenases. Structure-activity effects.
Kelley, M; Lambert, I; Merrill, J; Safe, S, 1985
)
0.27
" The dose-response relationships for hepatic CYP2B induction by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) were examined in the male F344/NCr rat."( Dose-response relationships for the induction of P450 2B by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzne (TCPOBOP) in rat and cultured rat hepatocytes.
Dragnev, KH; Jones, CR; Lubet, RA; Mellini, DW; Nims, RW; Sinclair, JF; Sinclair, PR; Thomas, PE, 1993
)
0.29
" Luminescence returned to baseline by 24-48 hours after drug injection and was reinducible over two additional rounds of drug dosing in pxr(+/+) mice."( Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.
Chen, J; Forman, BM; Gu, L; Kane, SE; Synold, TW, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID1705
Chain A, Ferritin light chainEquus caballus (horse)Potency44.66845.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency18.12230.100020.879379.4328AID588453
AR proteinHomo sapiens (human)Potency68.58960.000221.22318,912.5098AID1259243
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency16.00310.001022.650876.6163AID1224838; AID1224893
retinoid X nuclear receptor alphaHomo sapiens (human)Potency24.22820.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.33650.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.58930.000229.305416,493.5996AID588514
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency54.94770.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency10.00000.001019.414170.9645AID588536
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency44.66840.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency33.34000.000723.06741,258.9301AID743085; AID743122
Histone H2A.xCricetulus griseus (Chinese hamster)Potency89.76250.039147.5451146.8240AID1224845
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency52.27590.006026.168889.1251AID488953; AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency31.56770.010039.53711,122.0200AID588545; AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency47.92610.000323.4451159.6830AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.28030.000627.21521,122.0200AID651741; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency37.93300.425612.059128.1838AID504536
gemininHomo sapiens (human)Potency5.17350.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency3.98110.125912.234435.4813AID1458
M-phase phosphoprotein 8Homo sapiens (human)Potency35.48130.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.28180.00106.000935.4813AID943
lamin isoform A-delta10Homo sapiens (human)Potency4.46680.891312.067628.1838AID1487
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.41251.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)IC50 (µMol)9.18400.36807.095518.0000AID602180; AID651639
corticotropin releasing factor-binding proteinHomo sapiens (human)IC50 (µMol)9.18400.36807.095518.0000AID602180; AID651639
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
corticotropin releasing factor-binding proteinHomo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID345646Effect on nuclear co-repressor receptor binding to mouse CAR L253F mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345547Effect on mouse CAR F171A mutant expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345670Decrease in steroid receptor coactivator 1 binding to mouse CAR T350M mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345754Decrease in mouse CAR N175A mutant activation expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345605Effect on steroid receptor co-activator 1 binding to mouse CAR F171L mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345539Activation of wild type mouse CAR expressed in HEK293 cells at 10 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345570Activation of mouse CAR I252L mutant expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345566Decrease in mouse CAR S251L mutant activation expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345544Increase in nuclear co-repressor receptor binding to wild type mouse CAR expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345632Effect on nuclear co-repressor receptor binding to mouse CAR S251L mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345597Effect on steroid receptor co-activator 1 binding to mouse CAR F171A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345664Decrease in steroid receptor coactivator 1 binding to mouse CAR T350A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345831Effect on steroid receptor co-activator 1 binding to mouse CAR L212A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345612Decrease in steroid receptor co-activator 1 binding to mouse CAR N175A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1209507Activation of human CAR expressed in rat hepatocytes coexpressing CYP2B1 at 1 uM after 24 hrs by dual luciferase reporter gene assay2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Species-dependent and receptor-selective action of bilobalide on the function of constitutive androstane receptor and pregnane X receptor.
AID345537Activation of wild type mouse CAR expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345594Effect on nuclear co-repressor receptor binding to mouse CAR F171A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345609Effect on nuclear co-repressor receptor binding to mouse CAR N175A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345639Effect on nuclear co-repressor receptor binding to mouse CAR I252L mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345573Effect on mouse CAR L253F mutant expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345656Decrease in steroid receptor coactivator 1 binding to mouse CAR Y336A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345624Effect on nuclear co-repressor receptor binding to mouse CAR H213A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345683Cytotoxicity against HEK293 cells2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345629Effect on steroid receptor co-activator 1 binding to mouse CAR H213A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345653Effect on nuclear co-repressor receptor binding to mouse CAR Y336A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345600Effect on nuclear co-repressor receptor binding to mouse CAR F171L mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345679Decrease in steroid receptor coactivator 1 binding to mouse CAR L353A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345542Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 2 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345550Effect on mouse CAR F171L mutant expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345558Activation of mouse CAR L212A mutant expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345667Effect on nuclear co-repressor receptor binding to mouse CAR T350M mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345635Effect on steroid receptor co-activator 1 binding to mouse CAR S251L mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345582Decrease in mouse CAR T350A mutant activation expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1209510Activation of human CAR expressed in human HepG2 cells coexpressing CYP2B6 at 0.25 uM after 24 hrs by dual luciferase reporter gene assay2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Species-dependent and receptor-selective action of bilobalide on the function of constitutive androstane receptor and pregnane X receptor.
AID345590Decrease in mouse CAR L353A mutant activation expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345586Decrease in mouse CAR T350M mutant activation expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345578Effect on mouse CAR Y336A mutant expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345661Effect on nuclear co-repressor receptor binding to mouse CAR T350A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345616Effect on nuclear co-repressor receptor binding to mouse CAR L212A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345674Effect on nuclear co-repressor receptor binding to mouse CAR L353A mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345642Enhancement of steroid receptor coactivator 1 binding to mouse CAR I252L mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345650Effect on steroid receptor coactivator 1 binding to mouse CAR L253F mutant expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345562Activation of mouse CAR H213A mutant expressed in HEK293 cells at 1 uM by mammalian one-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345541Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 1 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID345543Enhancement of steroid receptor coactivator 1 binding to wild type mouse CAR expressed in HEK293 cells at 10 uM by yeast two-hybrid assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Ligand specificity of constitutive androstane receptor as probed by induced-fit docking and mutagenesis.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346793Mouse Constitutive androstane receptor (1I. Vitamin D receptor-like receptors)2000Molecular and cellular biology, May, Volume: 20, Issue:9
The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (174)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (8.62)18.7374
1990's18 (10.34)18.2507
2000's52 (29.89)29.6817
2010's78 (44.83)24.3611
2020's11 (6.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.71 (24.57)
Research Supply Index5.17 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other174 (99.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]